Novo Nordisk has blockbuster hopes for its GLP-1 semaglutide type 2 diabetes drug, which is edging towards approval in major markets – but it won't have a cardiovascular protection indication.

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

If approved for the new indication, it could add a major new growth driver for semaglutide, which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity ...

Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight loss has captured more public attention.

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

The expanding indications, technological advancements, and strong pipeline developments are shaping the future of this dynamic market. The Semaglutide Market valued at USD 5.76 billion in 2023 and ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide ... need for reimbursement models that support expanded indications. Additionally, increased adoption of these ...